Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5101748 | 0.87 | CYP3A4 (0.57) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL10492784 | 0.85 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5108203 | 0.84 | LMNA (0.51) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5108127 | 0.84 | CYP3A4 (0.49) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL5108811 | 0.83 | CYP3A4 (0.48) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL31302008 | 0.83 | CYP3A4 (0.48) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL11758391 | 0.82 | CYP3A4 (0.50) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 | |
| SCHEMBL1496409 | 0.82 | SMN1; SMN2 (0.60) | ALDH1A1SMN1; SMN2MAPTNPC1LMNA | |
| SCHEMBL5108151 | 0.82 | KMT2A (0.49) | CYP3A4SMN1; SMN2TDP1MAPTNPC1 | |
| SCHEMBL5946823 | 0.80 | CYP3A4 (0.48) | CYP3A4ALDH1A1TSHRHSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
| US-7342005-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2008-03-11 | — | — | US | disclosed |
| EP-1833806-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | AstraZeneca AB (SE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006064189-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | WO | disclosed |
| US-7041836-B2 | Antibiotic compounds | ASTRAZENECA UK LIMITED (GB) | 2006-05-09 | — | — | US | disclosed |
| US-20050209212-A1 | Antibiotic compounds | ASTRAZENECA UK LIMITED | 2005-09-22 | — | — | US | disclosed |
| US-20030144264-A1 | Antibiotic compounds | ZENECA LIMITED | 2003-07-31 | — | — | US | disclosed |
| US-6521612-B2 | Antibiotic against grampositive, gramnegative bacteria | ZENECA LTD. (GB) | 2003-02-18 | — | — | US | disclosed |
| US-20020042408-A1 | Antibiotic compounds | ZENECA LIMITED | 2002-04-11 | — | — | US | disclosed |
| US-6187804-B1 | Antibiotic compounds | ZENECA LIMITED (GB) | 2001-02-13 | — | — | US | disclosed |
| US-5856321-A | PREPARATION OF CARBAPENEMS | ZENECA LIMITED (GB) | 1999-01-05 | — | — | US | disclosed |
| EP-0579826-B1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LTD (GB) | 1998-11-11 | — | — | EP | disclosed |
| CN-1036006-C | Antibiotic compounds | ZENECA LTD (GB) | 1997-10-01 | — | — | CN | disclosed |
| US-5652233-A | CARBAPENICILLINS | ZENECA LIMITED (GB) | 1997-07-29 | — | — | US | disclosed |
| US-5478820-A | Carbapenem deivatives; bactericides | ZENECA LTD. (GB) | 1995-12-26 | — | — | US | disclosed |
| EP-0579826-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1994-01-26 | — | — | EP | disclosed |
| CN-1079224-A | Antifungal compound | ZENECA LTD (GB) | 1993-12-08 | — | — | CN | disclosed |
| WO-1993015078-A1 | CARBAPENEMS CONTAINING A CARBOXY SUBSTITUTED PHENYL GROUP, PROCESSES FOR THEIR PREPARATION, INTERMEDIATES AND USE AS ANTIBIOTICS | ZENECA LIMITED (GB) | 1993-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | CYP3A4 551/4885ALDH1A1 314/4885TSHR 1451/4885 |
| US-20050209212-A1 | Antibiotic compounds | NRDC, NPR3, NGLY1 | CYP3A4 1010/4885ALDH1A1 3269/4885TSHR 3766/4885 |
| US-20020042408-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | CYP3A4 631/4885ALDH1A1 1382/4885TSHR 3965/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | CYP3A4 544/4885ALDH1A1 303/4885TSHR 1169/4885 |
| US-20030144264-A1 | Antibiotic compounds | NRDC, NGLY1, NR4A1 | CYP3A4 745/4885ALDH1A1 1579/4885TSHR 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.